诚志股份有限公司独立董事 对公司第八届董事会第五次会议相关议案的独立意见 诚志股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日召开了第八届 董事会第五次会议，我们作为公司独立董事，根据《上市公司治理准则》、《上 市公司独立董事规则》、《深圳证券交易所股票上市规则》和公司《章程》及其 他相关法律、法规的规定，对本次董事会议案进行了审查和监督。现基于我们独 立、客观的判断发表如下独立意见： 一、关于公司 2023 年上半年计提资产减值准备的独立意见 经审核，我们认为：公司本次计提资产减值准备事项依据充分、程序合法， 符合《企业会计准则》、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》和公司相关制度等规定，能更加真实、准确地反映公司的 资产状况和经营成果，没有损害中小股东的合法权益。 王欣新 王建业 郭亚雄 综上，我们同意本次计提资产减值准备的议案，并将该议案提交公司 2023 年第二次临时股东大会审议。 二、关于公司为控股子公司诚志华青化工提供担保的独立意见 经审核，我们认为：公司本次对外担保对象为公司全资子公司，担保总额度 为 9 亿元，为其贷款提供担保的财务风险处 ...

诚志股份有限公司2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 诚志股份有限公司2023年半年度非经营性资金占用及其他关联资金往来情况汇总表（续） 单位：万元 | 其他关联 | 资金往来方名称 | 往来方与上市公司 | 上市公司核算 | 2023年期初往来 | 2023年半年度往 | 2023年半年度偿 | 2023年6月30日 | 往来形成原因 | 往来性质（经 营性往来、非 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金往来 | | 的关联关系 | 的会计科目 | 资金余额 | 来累计发生金额 | 还累计发生金额 | 往来资金余额 | | 经营性往来） | | 控股股东、实际 控制人及其附属 | | | | | | | | | | | 企业 | | | | | | | | | | | 上市公司的子公 | 安徽诚志显示玻璃有限公司 | 控股子公司 | 其他应收款 | 6,100.00 | 650.87 | 150.87 | 6,600.00 | 资金拆借 | 非经营性往来 | | | 诚志生命科技有限公司 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000990 证券简称：诚志股份 公告编号：2023-046 诚志股份有限公司 关于为子公司诚志华青化工提供担保的公告 一、担保情况概述 2023 年 8 月 10 日，诚志股份有限公司（以下简称"公司"）第八届董事会 第五次会议审议通过了《关于公司为控股子公司诚志华青化工提供担保的议案》。 因业务发展的需要，公司董事会同意为青岛诚志华青化工新材料有限公司（以下 简称"诚志华青化工"）申请的总额 9 亿元银行授信额度提供担保。 截止公告日，公司担保总额为 120,089 万元，没有对合并报表外单位提供担 保。担保事项具体实施时，公司将及时履行信息披露义务。 二、被担保人基本情况 公司名称：青岛诚志华青化工新材料有限公司 成立日期：2022年6月17日 注册资本：16,600万元 注册地址：山东省青岛市黄岛区青岛董家口化工产业园内港兴大道 66 号 法定代表人：龙大伟 公司类型：有限责任公司(非自然人投资或控股的法人独资) 经营范围：一般项目：新材料技术研发；化工产品生产（不含许可类化工产 品）；化工产品 ...

证券代码：000990 证券简称：诚志股份 公告编号：2023-030 诚志股份有限公司 关于参加江西辖区上市公司2023年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，诚志股份有限公司（以下简称"公司"） 将参加由江西证监局、江西省上市公司协会与深圳市全景网络有限公司联合举办 的"2023 年江西辖区上市公司投资者网上集体接待日活动"，现将相关事项公 告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2023 年 5 月 19 日（星期五）14:30-17:00。届 时公司副总裁、董事会秘书邹勇华先生，财务总监梁晋先生将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划和可持续发展等投资者关 心的问题，与投资者进行沟通与交流。 欢迎广大投资者积极参与。 特此公告。 诚志股份有限公司 董事会 2023 年 5 月 16 日 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥3,365,397,917.36, a slight increase of 0.18% compared to ¥3,359,509,487.18 in the same period last year[5] - The net profit attributable to shareholders was -¥56,979,827.62, representing a significant decline of 138.93% from ¥146,377,568.96 in Q1 2022[5] - The total profit for the period was -¥36,862,134.11, a decline of 117.64% compared to ¥208,955,055.34 in the same period last year[11] - The basic earnings per share were -¥0.0469, down 138.92% from ¥0.1205 in the same period last year[5] - The net profit for the current period was CNY -7,586,194.79, a decrease from CNY 32,321,373.12 in the previous period, reflecting a substantial decline in profitability[42] - The comprehensive income total for the current period was CNY -29,142,455.84, compared to CNY 176,235,764.87 in the previous period, indicating a drastic change in overall financial health[42] Cash Flow - The net cash flow from operating activities was -¥201,611,413.38, a decrease of 334.98% compared to ¥85,797,720.18 in the previous year[5] - Cash flow from investment activities decreased by 58.36% to 525,437,338.73 CNY, primarily due to a reduction in current financial investments[13] - Cash flow from financing activities increased by 127.36% to 1,350,299,146.64 CNY, mainly due to an increase in bank borrowings[16] - The net increase in cash and cash equivalents decreased by 58.39% to 300,038,334.58 CNY, attributed to higher procurement expenditures and reduced net financing[16] - The company reported a total cash outflow from operating activities of CNY 3,652,795,458.21, compared to CNY 3,198,370,275.94 last year, reflecting an increase of approximately 14.2%[49] - The company's cash flow from tax refunds was CNY 30,390,212.43, significantly higher than CNY 4,358,718.15 in the previous year, indicating a growth of about 596.5%[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥24,500,331,603.64, a decrease of 0.10% from ¥24,525,690,795.99 at the end of the previous year[5] - The total liabilities increased to CNY 6,060,551,192.95 from CNY 6,012,672,557.92, showing a rise in financial obligations[42] - The total equity attributable to shareholders decreased to CNY 17,565,291,498.62 from CNY 17,666,233,214.30, reflecting a decline in shareholder value[42] Expenses - The company's management expenses decreased by 33.15% to ¥143,529,356.08 from ¥214,716,224.91 in Q1 2022[9] - The company experienced a significant increase in sales expenses, which totaled CNY 28,863,793.61, down from CNY 40,815,751.02 in the previous period, suggesting cost-cutting measures[42] - Research and development expenses were CNY 63,338,693.64, slightly up from CNY 60,536,692.05 in the previous period, indicating continued investment in innovation[42] Investments and Acquisitions - The company plans to invest RMB 10 billion to establish a wholly-owned subsidiary, Qingdao Chengzhi Huqing New Materials Co., Ltd., in Qingdao[21] - The company is investing approximately RMB 4 billion in the POE project and RMB 800 million in the ultra-high molecular weight polyethylene project through its subsidiary Qingdao Huqing[21] - The company has completed the acquisition of 100% equity in Qingdao Chengzhi Huqing Chemical New Materials Co., Ltd. for RMB 207 million[32] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,651, with the largest shareholder holding 30.83% of the shares[17] - The top ten shareholders accounted for a significant portion of the company's equity, with the largest shareholder holding 374,650,564 shares[17] Operational Developments - The company is in the process of splitting its subsidiary Beijing Chengzhi Yonghua for a potential IPO, with preparations currently underway[25] - The company has signed an agreement to accelerate the construction of the first hydrogen refueling station in Changshu, which has passed all necessary inspections and is now operational[28] - The company is coordinating the delivery of facilities for its subsidiary Yunnan Hanmeng Pharmaceutical's industrial hemp project[23] - The company has reached an agreement with Wan Sheng Bioengineering for a repayment plan regarding a debt of approximately RMB 133.18 million[25]

证券代码：000990 证券简称：诚志股份 公告编号：2023-023 诚志股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 诚志股份有限公司（以下简称"公司"）《2022 年年度报告》已于 2023 年 3 月 25 日在指定信息披露媒体披露。为便于广大投资者更加全面深入地了解公 司经营业绩、发展战略等情况，公司定于 2023 年 4 月 17 日（星期一）15:00-17:00 在"价值在线"（www.ir-online.cn）举办 2022 年度网上业绩说明会，与投资者 进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 4 月 17 日（星期一）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 诚志股份有限公司 董事会 2023 年 4 月 8 日 公司董事、总裁韦俊民先生，董事、副总裁李瑞先生，独立董事王欣新先生， 副总裁、董事会秘书邹勇华先生，财务总监梁晋先生。 三 ...

Financial Performance - The company's operating revenue for 2022 was ¥11,717,284,386.82, a decrease of 3.83% compared to ¥12,183,915,609.68 in 2021[14] - The net profit attributable to shareholders for 2022 was ¥52,879,612.83, representing a significant decline of 94.76% from ¥1,008,442,260.98 in the previous year[14] - The net profit after deducting non-recurring gains and losses was ¥21,685,858.60, down 97.97% from ¥1,066,834,716.95 in 2021[14] - The company's cash flow from operating activities was ¥1,358,588,166.91, a decrease of 19.82% compared to ¥1,694,386,012.09 in 2021[14] - The total sales revenue for 2022 was 9,078,653,285.31 yuan, a decrease of 10.36% compared to 2021[70] - The company reported a total revenue of 1,176,211,785.80 yuan from propylene sales, with an average price of 7,831 yuan per ton in 2022[47] - Ethylene sales generated revenue of 2,129,209,399.03 yuan, maintaining an average price of 8,149 yuan per ton in 2022[47] - The clean energy products segment generated CNY 9.74 billion in revenue, accounting for 83.14% of total revenue, but saw a decline of 5.31% year-on-year[46] - Semiconductor display materials revenue increased by 15.17% year-on-year to CNY 1.23 billion, representing 10.52% of total revenue[46] - The life medical services segment reported revenue of CNY 657.58 million, down 10.72% year-on-year[46] Assets and Investments - The total assets at the end of 2022 were ¥24,525,690,795.99, an increase of 0.32% from ¥24,447,250,885.01 at the end of 2021[14] - The net assets attributable to shareholders at the end of 2022 were ¥17,666,233,214.30, slightly up by 0.08% from ¥17,651,704,619.24 in 2021[14] - The company reported a total of 6,754,694,927.52 yuan in goodwill, which accounted for 27.54% of total assets[60] - Short-term loans increased by 3.07% to 2,655,000,000.00 yuan, representing 10.83% of total assets[60] - The company’s financial assets increased to CNY 4,218,609,879.49, with a total purchase amount of CNY 628,000,000.00 during the reporting period[81] - The investment property value increased to CNY 2,506,986,603.84, reflecting a fair value change gain of CNY 24,467,390.47 during the reporting period[81] Research and Development - Research and development investment reached approximately CNY 162 million, with 25 projects initiated during the reporting period[29] - The company is actively engaged in R&D projects aimed at enhancing product performance and expanding production capabilities, including the mass production of G6 large panels[56] - The company is focusing on R&D for new materials and technologies, including OLED and quantum dot materials, to diversify its product structure[149] - The number of R&D personnel increased by 6.75% to 427 employees[77] - Research and development expenses decreased by 11.21% to 260,213,223.18 yuan in 2022[75] Strategic Focus and Market Position - The company is focusing on the health sector, with expectations that the health service industry in China will exceed ¥11.5 trillion by 2025, becoming the second-largest market globally[21] - The company is actively pursuing energy transition innovations to contribute to national carbon neutrality goals[29] - The company is focusing on long-term strategic partnerships with major clients to ensure stable operations[29] - The company aims to increase revenue and profit by diversifying its product offerings and improving production efficiency[56] - The company is exploring market expansion opportunities and enhancing its competitive position in the industry through strategic initiatives[56] Corporate Governance and Compliance - The company has established a complete independent operational system, ensuring business, personnel, asset, and financial independence from its controlling shareholders[139] - The company has implemented a risk prevention mechanism to effectively resist sudden risks[157] - The board of directors has set up four specialized committees to enhance decision-making and governance[157] - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations[157] - The company is committed to maintaining transparency and accuracy in information disclosure, adhering to relevant laws and regulations[138] Market Challenges and Responses - The company faces market risks due to macroeconomic conditions and potential fluctuations in raw material prices[152] - The company emphasizes strict cost control and customer retention strategies to stabilize its market position[149] - The company implemented flexible marketing strategies and strict quality control measures to navigate the reduced domestic market demand[187] - Despite the challenging market, the company maintained its leading market share in monochrome products and achieved simultaneous growth in product sales, revenue, and net profit[187] - The company is actively exploring new markets and technologies to ensure sustainable growth in the future[187] Future Outlook - The company has set a revenue guidance for 2023, projecting a growth of 12% to 1.68 billion RMB[200] - New product launches are expected to contribute an additional 200 million RMB in revenue in 2023[200] - Market expansion plans include entering three new provinces in China, targeting a 5% market share increase in these regions[200] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for this purpose[200] - Strategic partnerships are being formed to leverage synergies in supply chain management, expected to reduce costs by 8%[200]